MEDNAX Inc (MD) Expected to Post Earnings of $0.84 Per Share

Analysts expect MEDNAX Inc (NYSE:MD) to post $0.84 earnings per share for the current fiscal quarter, according to Zacks Investment Research. Seven analysts have issued estimates for MEDNAX’s earnings, with the lowest EPS estimate coming in at $0.75 and the highest estimate coming in at $0.88. MEDNAX reported earnings of $0.75 per share during the same quarter last year, which indicates a positive year-over-year growth rate of 12%. The company is expected to issue its next earnings results on Thursday, April 19th.

According to Zacks, analysts expect that MEDNAX will report full-year earnings of $4.22 per share for the current fiscal year, with EPS estimates ranging from $4.02 to $4.35. For the next financial year, analysts expect that the business will post earnings of $4.50 per share, with EPS estimates ranging from $4.32 to $4.73. Zacks Investment Research’s EPS averages are a mean average based on a survey of research firms that cover MEDNAX.

MEDNAX (NYSE:MD) last announced its quarterly earnings data on Thursday, February 8th. The company reported $0.87 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.83 by $0.04. MEDNAX had a return on equity of 10.10% and a net margin of 9.26%. The firm had revenue of $910.82 million for the quarter, compared to analysts’ expectations of $884.55 million. During the same period last year, the business posted $1.00 earnings per share. The firm’s revenue for the quarter was up 9.6% on a year-over-year basis.

MD has been the topic of several research analyst reports. Piper Jaffray Companies initiated coverage on MEDNAX in a research note on Wednesday, December 13th. They set an “overweight” rating and a $58.00 price objective on the stock. SunTrust Banks set a $55.00 price objective on MEDNAX and gave the stock a “hold” rating in a research note on Thursday, December 21st. Zacks Investment Research upgraded MEDNAX from a “hold” rating to a “buy” rating and set a $60.00 price objective on the stock in a research note on Tuesday, January 23rd. Stifel Nicolaus restated a “hold” rating and set a $56.00 price objective on shares of MEDNAX in a research note on Wednesday, January 24th. Finally, Mizuho set a $49.00 price objective on MEDNAX and gave the stock a “hold” rating in a research note on Wednesday, January 24th. Two research analysts have rated the stock with a sell rating, nine have given a hold rating and four have given a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $55.58.

Shares of MEDNAX (NYSE MD) traded down $0.01 on Friday, reaching $57.46. The company had a trading volume of 800,078 shares, compared to its average volume of 908,024. MEDNAX has a 52-week low of $40.56 and a 52-week high of $70.72. The company has a market capitalization of $5,389.52, a PE ratio of 18.30, a PEG ratio of 1.42 and a beta of 0.26. The company has a debt-to-equity ratio of 0.60, a current ratio of 1.18 and a quick ratio of 1.18.

In other MEDNAX news, insider John C. Pepia sold 3,000 shares of the firm’s stock in a transaction on Tuesday, March 13th. The stock was sold at an average price of $58.35, for a total value of $175,050.00. Following the sale, the insider now directly owns 39,716 shares in the company, valued at $2,317,428.60. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 2.40% of the company’s stock.

Several institutional investors and hedge funds have recently modified their holdings of MD. Fuller & Thaler Asset Management Inc. acquired a new position in shares of MEDNAX during the third quarter valued at $103,000. Meiji Yasuda Asset Management Co Ltd. increased its holdings in shares of MEDNAX by 45.3% during the third quarter. Meiji Yasuda Asset Management Co Ltd. now owns 5,230 shares of the company’s stock valued at $226,000 after purchasing an additional 1,630 shares during the period. Delta Capital Management LLC acquired a new position in shares of MEDNAX during the fourth quarter valued at $227,000. Brown Advisory Inc. acquired a new position in shares of MEDNAX during the fourth quarter valued at $231,000. Finally, YHB Investment Advisors Inc. acquired a new position in shares of MEDNAX during the fourth quarter valued at $235,000. 98.53% of the stock is currently owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “MEDNAX Inc (MD) Expected to Post Earnings of $0.84 Per Share” was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this piece on another publication, it was copied illegally and republished in violation of U.S. & international trademark & copyright legislation. The original version of this piece can be read at https://sportsperspectives.com/2018/03/19/mednax-inc-md-expected-to-post-earnings-of-0-84-per-share.html.

MEDNAX Company Profile

MEDNAX, Inc is a provider of physician services, including newborn, anesthesia, maternal-fetal, teleradiology, pediatric cardiology and other pediatric subspecialty care. As of December 31, 2016, the Company’s national network consisted of over 3,600 affiliated physicians, including over 1,130 physicians providing neonatal clinical care, in 35 states and Puerto Rico, primarily within hospital-based neonatal intensive care units (NICUs), to babies born prematurely or with medical complications.

Get a free copy of the Zacks research report on MEDNAX (MD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for MEDNAX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply